Peptide Library

FDA-approved

Sexual & reproductive

Lutetium Lu-177 vipivotide tetraxetan

Evidence

FDA approved

Class

Radioligand therapy targeting PSMA

/

Lutetium Lu-177 vipivotide tetraxetan

KEY TAKEAWAY

Lutetium Lu 177 vipivotide tetraxetan is a small PSMA-binding peptide-like molecule carrying radioactive lutetium. It is sold as Pluvicto. The FDA approved Pluvicto in 2022 for PSMA-positive metastatic castration-resistant prostate cancer, and later for an earlier stage of disease.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Radioligand therapy targeting PSMA

Approved for

PSMA-positive metastatic castration-resistant prostate cancer

Key fact

The FDA approved Pluvicto in 2022 for PSMA-positive metastatic castration-resistant prostate cancer, and later for an earlier stage of disease.

Route

Intravenous infusion in a series of treatments

Evidence strength

FDA approved

What it is

What it is

Lutetium Lu 177 vipivotide tetraxetan is a small PSMA-binding peptide-like molecule carrying radioactive lutetium. It is sold as Pluvicto.

How it works

How it works

It binds prostate-specific membrane antigen on prostate cancer cells and delivers radiation directly to them.

Regulatory status

Regulatory status

The FDA approved Pluvicto in 2022 for PSMA-positive metastatic castration-resistant prostate cancer, and later for an earlier stage of disease.

What it is used for

What it is used for

PSMA-positive metastatic castration-resistant prostate cancer.

Side effects and risks

Side effects and risks

Dry mouth, fatigue, nausea, low blood counts and kidney effects are the main concerns. Radiation-safety precautions apply.

Citations

Citations

U.S. FDA prescribing information for Lutetium Lu-177 vipivotide tetraxetan. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo